EMA Recommended Ocrevus for Pediatric MS Patients
The regulatory body endorsed expanding the drug's use to include children aged 10 and older with relapsing forms.
Updated on Sept. 22, 2026 in Stroke
Live Poll
Should regulators approve high-efficacy drugs for children based on adult trial data and limited pediatric studies?
The European Medicines Agency has recommended the approval of Ocrevus for pediatric patients aged 10 and older diagnosed with relapsing multiple sclerosis. This expansion of the drug's current adult marketing authorization follows positive data from a recent clinical trial.
Why it matters
Extending this therapy to adolescents aims to address pediatric-onset multiple sclerosis by reducing inflammatory activity and disease progression early in life. The recommendation marks a potential shift in standard treatment options for younger populations currently living with the condition.
The Phase 3 OPERETTA 2 trial included 187 patients aged 10 to 17 years to evaluate efficacy. The medication, a monoclonal antibody targeting CD20 protein on B cells, is administered via intravenous infusion.
The players
European Medicines Agency
This is the primary agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
European Commission
This is the politically independent executive arm of the European Union that is responsible for proposing legislation and implementing decisions.
The details
Ocrelizumab works by depleting CD20-positive B cells, which helps lower inflammation within the central nervous system. Following the recommendation from the agency, regulators will now move toward a final marketing authorization decision.
Timeline
September 22, 2026: The recommendation was finalized.
The Big Picture
This move follows the protocol established by the OPERETTA 2 clinical trial, which provided the necessary framework to validate monoclonal antibody use in children. It signals a move toward incorporating targeted biologic therapies earlier in the treatment landscape for pediatric-onset relapsing multiple sclerosis.
This development could soon provide pediatric patients with access to an intravenous treatment option previously reserved for adults. Families should discuss potential side effects and the specifics of the infusion schedule with their healthcare providers as guidelines evolve.
The takeaway
Expanding approved treatment options for pediatric multiple sclerosis allows clinicians to intervene earlier with targeted therapies. Patients and their families should prepare to review new guidance from health authorities once the final authorization is confirmed.
What happens next
The European Commission must now issue a final decision regarding the marketing authorization of Ocrevus for pediatric use, after which the EMA will publish updated prescribing information.
Further reading
Learn more about the latest developments in neurological care at Stroke.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulators approve high-efficacy drugs for children based on adult trial data and limited pediatric studies?
